Implications of Immune System in Stroke for Novel Therapeutic Approaches

Aaron A. Hall, Keith R. Pennypacker

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Each year, approximately 795,000 people suffer a new or recurrent stroke. About 610,000 of these are first attacks, and 185,000 are recurrent attacks. Currently, the only FDA approved treatment for ischemic stroke is the thrombolytic recombinant tissue plasminogen activator (Alteplase), which must be given within 4.5 h of stroke onset. Beyond this time, apoptotic and inflammatory processes greatly diminish the therapeutic benefits of current treatments. While there have been many experimental treatments for stroke that showed promising preclinical efficacy, these treatments have failed to show efficacy in clinical trials. In many of these cases, the preclinical animal studies did not model the clinical setting effectively. The injury that occurs following stroke is a dynamic process. To effectively treat stroke patients at clinically relevant timepoints, it is imperative to understand both the humeral and cell-mediated phenomena that occur throughout the body in response to ischemic injury over time. Promising experimental therapeutics designed to be given 1 to 2 days following stroke require both neuroprotective and anti-inflammatory properties in order to be efficacious.

Original languageEnglish
Pages (from-to)85-95
Number of pages11
JournalTranslational Stroke Research
Issue number2
StatePublished - 2010

Bibliographical note

Funding Information:
Acknowledgments This work was supported by the National Institute of Neurological Disorders and Stroke (5R21NS060907 to K.R.P.) and the American Heart Association (0715096B to A.A.H.).


  • Cord blood
  • Microglia
  • Middle cerebral artery occlusion
  • Neuron
  • Sigma receptor
  • Spleen

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Implications of Immune System in Stroke for Novel Therapeutic Approaches'. Together they form a unique fingerprint.

Cite this